Patents by Inventor Dana Elias
Dana Elias has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8828922Abstract: The present invention relates to a method for suppression, prevention, delaying the onset or treatment of diabetes, by administering to an individual in need thereof a fragment of Hsp60 or analog thereof in conjunction with a low antigenicity diet. The invention is exemplified using DiaPep277™, an analog of residues 437-460 of human Hsp60 in combination with a hydrolyzed casein diet.Type: GrantFiled: February 15, 2012Date of Patent: September 9, 2014Assignee: Andromeda Biotech Ltd.Inventors: Johannes Rozing, Dana Elias
-
Publication number: 20120142588Abstract: The present invention relates to a method for suppression, prevention, delaying the onset or treatment of diabetes, by administering to an individual in need thereof a fragment of Hsp60 or analog thereof in conjunction with a low antigenicity diet. The invention is exemplified using DiaPep277™, an analog of residues 437-460 of human Hsp60 in combination with a hydrolyzed casein diet.Type: ApplicationFiled: February 15, 2012Publication date: June 7, 2012Applicant: ANDROMEDA BIOTECH LTD.Inventors: Johannes Rozing, Dana Elias
-
Patent number: 7576177Abstract: According to the present invention it is now disclosed that exposure of antigen presenting cells, particularly dendritic cells, to peptides or peptide analogs derived from heat shock proteins will subsequently activate T cells to produce immunomodulatory cytokines and will directly influence the cytokines, chemokines, and surface antigens produced by the exposed antigen presenting cells. The present invention relates to peptides and peptide analogs of heat shock proteins capable of interacting directly with dendritic cells. The present invention further relates to pharmaceutical compositions that include dendritic cells exposed to such peptides and analogs, useful for prevention or treatment of either inflammatory disorders and autoimmune diseases or malignancies, viral infections and allergy.Type: GrantFiled: July 30, 2004Date of Patent: August 18, 2009Assignee: Andromeda Biotech Ltd.Inventors: Yoram Karmon, Ann Avron, Dana Elias
-
Publication number: 20090170777Abstract: The present invention relates to a method for suppression, prevention, delaying the onset or treatment of diabetes, by administering to an individual in need thereof a fragment of Hsp60 or analog thereof in conjunction with a low antigenicity diet. The invention is exemplified using DiaPep277™, an analog of residues 437-460 of human Hsp60 in combination with a hydrolyzed casein diet.Type: ApplicationFiled: February 25, 2009Publication date: July 2, 2009Inventors: Johannes Rozing, Dana Elias
-
Publication number: 20070060519Abstract: The present invention fragments and analogs of heat shock proteins in combination with a low antigenicity diet for suppression, prevention and treatment of diabetes. The invention is exemplified using DiaPep277™, an analog of residues 437-460 of human Hsp60 in combination with a hydrolyzed casein diet. The invention further relates to orally active pharmaceutical compositions comprising Hsp60 fragments and analogs, such as DiaPep277, useful for suppression, prevention or treatment of diabetes and to a regimen for delaying the onset of type 1 diabetes and for inhibition of insulitis.Type: ApplicationFiled: July 27, 2006Publication date: March 15, 2007Inventors: Johannes Rozing, Dana Elias
-
Publication number: 20050163746Abstract: According to the present invention it is now disclosed that exposure of antigen presenting cells, particularly dendritic cells, to peptides or peptide analogs derived from heat shock proteins will subsequently activate T cells to produce immunomodulatory cytokines and will directly influence the cytokines, chemokines, and surface antigens produced by the exposed antigen presenting cells. The present invention relates to peptides and peptide analogs of heat shock proteins capable of interacting directly with dendritic cells. The present invention further relates to pharmaceutical compositions that include dendritic cells exposed to such peptides and analogs, useful for prevention or treatment of either inflammatory disorders and autoimmune diseases or malignancies, viral infections and allergy.Type: ApplicationFiled: July 30, 2004Publication date: July 28, 2005Inventors: Yoram Karmon, Ann Avron, Dana Elias
-
Publication number: 20040022777Abstract: The invention identifies fragments of hsp60 which retain the capability of inducing a pro-inflammatory immune response of cells of the innate immune system. It is further discloses the unexpected finding that smaller peptides derived from these fragments of hsp60 are capable of acting as antagonists of hsp60 insofar as they have the ability to reduce or even prevent the induction of a pro-inflammatory immune response by hsp60 in cells of the innate immune system. It further discloses variants, derivatives and analogs of such peptides, which are capable of acting as antagonists of hsp60 insofar as they have the ability to reduce or prevent the induction of a pro-inflammatory immune response by hsp60 in cells of the immune system. The invention also discloses pharmaceutical compositions comprising such peptide fragments or variants, derivatives and analogs thereof, and their use to prevent or ameliorate inflammatory diseases or disorders.Type: ApplicationFiled: June 13, 2002Publication date: February 5, 2004Inventors: Hubert Kolb, Dana Elias
-
Patent number: 6682897Abstract: Novel peptides which are epitopes of the human 60 kDa heat shock protein (hsp60) may be used for the diagnosis and treatment of insulin-dependent diabetes mellitus (IDDM). Pharmaceutical compositions containing such peptides and kits for use in diagnosis of IDDM are also disclosed.Type: GrantFiled: July 11, 2000Date of Patent: January 27, 2004Assignee: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Dana Elias, Rivka Abulafia, Jana Bockova
-
Publication number: 20030190323Abstract: The present invention provides pharmaceutical compositions and methods for reducing the incidence or severity of insulin dependent diabetes mellitus, insulitis, &bgr;-cell destruction, or latent autoimmune diabetes in adults by administering to a patient a pharmaceutical composition comprising an antigen and a carrier, wherein the antigen is recognized by inflammatory T cells associated with the pathogenesis of the disease and the carrier is a metabolizable lipid emulsion. The composition induces a TH1→TH2 shift in the cytokines produced by said T cells and it is administered in an amount, which is therapeutically effective to reduce the symptoms of the disease.Type: ApplicationFiled: December 2, 2002Publication date: October 9, 2003Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Irun R. Cohen, Dana Elias, Meir Shinitzky
-
Patent number: 6488933Abstract: Metabolizable lipid emulsions, such as Intralipid and Lipofundin, are excellent vehicles for peptide therapy of autoimmune diseases and of other TH1 T cell mediated diseases or conditions, as it promotes a TH1 to TH2 cytokine shift.Type: GrantFiled: April 19, 1998Date of Patent: December 3, 2002Assignee: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Dana Elias, Meir Shinitzky
-
Publication number: 20020086030Abstract: Metabolizable lipid emulsions, such as Intralipid and Lipofundin, are excellent vehicles for peptide therapy of autoimmune diseases and of other TH1 T cell mediated diseases or conditions, as it promotes a TH1 to TH2 cytokine shift.Type: ApplicationFiled: April 19, 1998Publication date: July 4, 2002Inventors: IRUN R COHEN, DANA ELIAS, MEIR SHINITZKY
-
Patent number: 6309847Abstract: It has been discovered that treatment of an IDDM model with the p277 auto-antigen in a tolerogenic carrier induces a shift from a TH1 T cell response to a TH2 T cell response. The efficacy of proposed vaccines for any T cell mediated disease can be detected or monitored by measuring for such a TH1→TH2 T cell reponse shift.Type: GrantFiled: July 22, 1998Date of Patent: October 30, 2001Assignee: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Dana Elias
-
Patent number: 6180103Abstract: A peptide having the structure of the p277 sequence of hsp60 in which one or both cysteine residues are replaced by valine residues and/or in which the Thr19 residue is replaced by Lys, has substantially the same biological activity as p277 but with substantially improved stability. The novel p277 analogues may be used for every purpose that p277 can be used.Type: GrantFiled: August 7, 1997Date of Patent: January 30, 2001Assignee: Yeda Research and Development Co., Ltd.Inventors: Irun R. Cohen, Dana Elias, Matityahu Fridkin
-
Patent number: 6110746Abstract: Novel peptides which are epitopes of the human 60 kDa heat shock protein (hsp60) may be used for the diagnosis and treatment of insulin-dependent diabetes mellitus (IDDM). Pharmaceutical compositions containing such peptides and kits for use in diagnosis of IDDM are also disclosed.Type: GrantFiled: April 27, 1998Date of Patent: August 29, 2000Assignee: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Dana Elias, Rivka Abulafia, Jana Bockova
-
Patent number: 6096314Abstract: The present invention relates generally to peptide sequences, and method of their use, which sequences modulate the activity of anti-idiotypic T cells. The activity of the anti-idiotypic T cells of interest is related to the ability of these T cells to recognize anti-p277 T cells. The peptides of the present invention thus include important tools in the effort to diagnose, prevent, alleviate or treat disease related to insulin-dependent diabetes mellitus (IDDM).Type: GrantFiled: June 30, 1997Date of Patent: August 1, 2000Assignee: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Dana Elias
-
Diagnosis and treatment of insulin dependent diabetes mellitus using heat shock protein determinents
Patent number: 5780034Abstract: A 65 KD heat shock protein, proteins cross-reactive therewith, antibodies thereto or T cells specific thereto can be used for detecting in humans the existence of, a tendency to develop, or the initiation of a process leading to insulin dependent diabetes mellitus. Antibodies to hsp65 can be used to detect the hsp65 molecule in blood or urine. The hsp65 molecule of any species, or any other substance immunologically cross-reactive therewith, when administered with a tolerogenic carrier, can be used for the prevention or treatment of IDDM prior to development of clinical symptoms thereof. T cells, active fragments thereof or the receptor peptide thereof can also be used for prevention or treatment of IDDM.Type: GrantFiled: February 3, 1995Date of Patent: July 14, 1998Assignee: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Dana Elias, Doron Markovits -
Patent number: 5671848Abstract: A 65 KD heat shock protein, proteins cross-reactive therewith, or antibodies thereto can be used for detecting in humans the existence of, a tendency to develop, or the initiation of a process leading to insulin dependent diabetes mellitus. Antibodies to hsp65 can be used to detect the hsp65 molecule in blood or urine. The hsp65 molecule of any species, or any other substance immunologically cross-reactive therewith, when administered with a tolerogenic carrier, can be used for the prevention or treatment of IDDM prior to development of clinical symptoms thereof.Type: GrantFiled: March 29, 1993Date of Patent: September 30, 1997Assignee: Yeda Research and Development Co. Ltd.Inventors: Irun Robert Cohen, Dana Elias, Doron Markovits
-
Patent number: 5578303Abstract: A 65 KD heat shock protein, proteins cross-reactive therewith, antibodies thereto or T cells specific thereto can be used for detecting in humans the existence of, a tendency to develop, or the initiation of a process leading to insulin dependent diabetes mellitus. Antibodies to hsp65 can be used to detect the hsp65 molecule in blood or urine. The hsp65 molecule of any species, or any other substance immunologically cross-reactive therewith, when administered with a tolerogenic carrier, can be used for the prevention or treatment of IDDM prior to development of clinical symptoms thereof. T cells, active fragments thereof or the receptor peptide thereof can also be used for prevention or treatment of IDDM.Type: GrantFiled: November 12, 1993Date of Patent: November 26, 1996Assignee: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Dana Elias, Doron Markovits
-
Patent number: 5114844Abstract: A 65 KD heat shock protein, proteins cross-reactive therewith, or antibodies thereto can be used for detecting in humans the existence of, a tendency to develop, or the initiation of a process leading to insulin dependent diabetes mellitus. Antibodies to hsp65 can be used to detect the hsp65 molecule in blood or urine. The hsp65 molecule of any species, or any other substance immunologically cross-reactive therewith, when administered with a tolerogenic carrier, can be used for the prevention or treatment of IDDM prior to development of clinical symptoms thereof.Type: GrantFiled: June 26, 1989Date of Patent: May 19, 1992Assignee: Yeda Research and Development Co., Ltd.Inventors: Irun R. Cohen, Dana Elias, Doron Markovits